Fact-checked by Grok 2 weeks ago

Orthostatic intolerance

Orthostatic intolerance (OI) is a condition characterized by the inability to tolerate an upright posture due to the development of symptoms and signs, such as , , , sweating, cognitive impairment, visual changes, and , which are relieved by lying down. It arises from inadequate cardiovascular and autonomic adjustments to gravitational stress upon standing, leading to reduced cerebral blood flow or excessive physiological responses. OI encompasses several distinct syndromes, including orthostatic hypotension (OH), defined as a sustained drop in systolic of at least 20 mm Hg or diastolic of at least 10 mm Hg within three minutes of standing; postural tachycardia (POTS), marked by a chronic increase in of more than 30 beats per minute (or 40 beats per minute in adolescents) upon standing without significant hypotension; initial orthostatic hypotension (IOH), involving a transient but profound drop immediately upon standing that resolves within 30 to 60 seconds; and vasovagal syncope (VVS), an episodic form featuring acute fainting due to cerebral hypoperfusion from and . These syndromes often overlap and can stem from underlying causes such as dysfunction, , low , venous pooling, or abnormalities. Epidemiologically, OI affects individuals across all ages, with VVS having a lifetime incidence of approximately 40% (peaking around age 15), estimated to impact approximately 1–3 million people in the United States (predominantly young women; as of 2024), recent studies noting an increase in cases following infection (as of 2025), and OH occurring in 16–30% of adults over 65 years (as of 2024). typically involves a detailed , orthostatic vital sign measurements, and provocation tests like the tilt-table or active stand test to reproduce symptoms and quantify hemodynamic changes. Management focuses on nonpharmacological measures, including hydration, salt loading, compression garments, physical counter-maneuvers (e.g., leg crossing or muscle tensing), and exercise reconditioning, with pharmacological options such as for , for volume expansion, or beta-blockers for control reserved for refractory cases.

Overview

Definition

Orthostatic intolerance (OI) is a clinical characterized by the development of symptoms due to cerebral hypoperfusion or sympathetic overactivity upon assuming or maintaining an upright posture, resulting from inadequate cardiovascular adaptation to gravitational stress. These symptoms are typically relieved by recumbency, distinguishing OI as a condition where upright posture becomes unsustainable due to failure in maintaining adequate cerebral blood flow. In healthy individuals, the normal orthostatic response involves rapid activation of the , which detects decreased arterial pressure from venous pooling in the lower body upon standing and compensates by increasing and inducing peripheral to preserve and cerebral . This autonomic ensures minimal disruption in upright , but in OI, the compensatory responses are insufficient, leading to the syndrome's hallmark features. The phenomenon was first described in the by Jacob Mendes Da Costa, who in 1871 reported orthostatic and related symptoms in veterans as "irritable heart" or "soldier's heart." The term "orthostatic intolerance" was later formalized in the 1990s through studies on post-spaceflight cardiovascular deconditioning, highlighting its relevance in microgravity environments. OI serves as an umbrella term encompassing various manifestations of orthostatic dysregulation, distinct from (OH), which refers specifically to a measurable drop in systolic of at least 20 mmHg or diastolic of 10 mmHg within three minutes of standing. Subtypes such as (POTS) and OH fall under OI but represent specific hemodynamic patterns.

Epidemiology

Orthostatic intolerance (OI) affects approximately 0.2% to 1% of the general population in developed countries, with postural orthostatic tachycardia syndrome (POTS), a common subtype, estimated to impact around 0.5% of women aged 15 to 50 years. Prevalence rates are higher among adolescents and young adults, with studies reporting up to 47% prevalence of POTS in subgroups such as those with generalized hypermobility spectrum disorder. OI predominantly affects females, with a female-to-male ratio of 4:1 to 5:1, and symptoms often peak during adolescence or perimenopause; it is more frequently reported among Caucasians, comprising about 93% of cases in large cohorts. POTS specifically has an incidence of about 6 per 100,000 person-years overall, rising to 10.5 per 100,000 among women (data from 2016). Comorbidities significantly influence incidence, with up to 80% co-occurrence in individuals with Ehlers-Danlos syndrome. Recognition of OI has increased following the , with 10% to 30% of cases exhibiting OI features in studies through 2025, including 31% prevalence in highly symptomatic cohorts. No strong seasonal variations are observed in OI distribution. Genetic predisposition contributes, with familial clustering reported in 10% to 20% of cases.

Clinical Presentation

Symptoms

Orthostatic intolerance manifests primarily through symptoms elicited by upright posture, including , , presyncope, , brain fog (manifesting as cognitive deficits such as impaired concentration and memory), , tremulousness, and . These symptoms typically onset within 10 minutes of standing and resolve promptly upon sitting or lying down, distinguishing them from non-postural complaints. Associated symptoms often include , , neck and shoulder pain, gastrointestinal disturbances such as bloating and abdominal discomfort, and . Sensory symptoms may encompass dysregulation, with patients experiencing heightened sensitivity to or due to autonomic involvement, as well as occasional visual scotomata or . In chronic forms, sleep disturbances can exacerbate overall fatigue. Symptoms vary in severity from mild and intermittent, occurring sporadically during triggers like prolonged standing or , to severe and daily disabling episodes that limit upright tolerance to less than 5-10 minutes. This graded impact significantly impairs , with studies indicating substantial functional limitations; for instance, patients with orthostatic intolerance report higher burdens across physical, anxiety/, and pain/discomfort domains compared to normative populations, often leading to interruptions in , , and daily activities in a majority of cases.

Acute Versus Chronic Forms

Orthostatic intolerance (OI) manifests in acute and chronic forms, distinguished primarily by their onset, duration, and clinical course. Acute OI typically presents with sudden onset triggered by transient factors such as , blood loss, or effects, leading to episodes that last from hours to days and often resolve spontaneously or with prompt intervention. Common examples include situational syncope or neurocardiogenic (vasovagal) syncope, where patients experience isolated events of presyncope or syncope without persistent daily impairment. In contrast, chronic OI is characterized by persistent symptoms occurring on most or all days for at least 6 months, often linked to underlying autonomic dysfunction or disorders such as . This form involves sustained hemodynamic instability, such as excessive heart rate increases upon standing in , and is associated with higher rates of , with approximately 25% of affected individuals unable to maintain employment due to daily symptoms and reduced . Chronic cases frequently involve comorbidities and progressive impairment in upright tolerance, leading to greater functional limitations compared to the self-limited nature of acute episodes. The transition from acute to chronic OI can occur, particularly in cases of untreated or recurrent acute episodes, such as those following viral infections. For instance, in post-viral syndromes like , up to 31% of patients with prolonged symptoms develop chronic OI, including , highlighting the risk of progression when initial hemodynamic disturbances are not addressed. Clinically, differentiation relies on history: acute OI features isolated, reversible events, while chronic OI presents with recurrent daily presyncope, fatigue, and associated autonomic symptoms, often requiring long-term management to mitigate prognostic differences like increased .

Pathophysiology

Hemodynamic Mechanisms

Upon assuming an upright , gravitational causes approximately 500 mL of blood to pool in the lower extremities within the first minute, with potential increases to 700-1000 mL over time if uncompensated. This pooling reduces venous return to the heart, leading to a transient decrease in by 20-30% in healthy individuals. In orthostatic intolerance (OI), this hemodynamic shift is exaggerated due to impaired compensatory responses, resulting in sustained reductions in preload and . Normal compensation involves rapid and increased to restore venous return and maintain ; however, in OI, these mechanisms fail, leading to a drop in systolic exceeding 20 mmHg or a increase greater than 30 beats per minute within three minutes of standing. Additionally, (CPP), defined as
CPP = MAP - ICP,
falls critically when (MAP) drops below 60 mmHg, impairing autoregulation in symptomatic cases.
Hypovolemia plays a central role in exacerbating these effects, occurring in nearly 50% of OI patients and worsening gravitational pooling by reducing overall circulating volume. This is particularly evident in the distinction between and peripheral pooling: while peripheral pooling affects leg veins, splanchnic hyperemia—excessive blood accumulation in abdominal capacitance vessels—contributes disproportionately in conditions like postural tachycardia syndrome, further diminishing . Ultimately, these hemodynamic disruptions culminate in cerebral hypoperfusion, with reduced by approximately 25% during orthostatic challenge in some patients compared to about 7% in healthy controls, triggering symptoms such as and presyncope due to inadequate .

Autonomic Dysfunction

Autonomic dysfunction plays a central role in orthostatic intolerance by impairing the nervous system's ability to maintain hemodynamic stability during postural changes. The , comprising sympathetic and parasympathetic branches, normally coordinates rapid adjustments in , vascular tone, and distribution to counteract upon standing. In orthostatic intolerance, disruptions in this coordination lead to inadequate compensatory responses, resulting in symptoms such as and syncope. A key feature is baroreflex impairment, where the arc fails to detect and respond appropriately to drops, leading to delayed or reduced sympathetic activation. This manifests as a blunted in norepinephrine, typically less than 200 pg/mL in the upright position, which hinders and cardiac acceleration needed to sustain . In some subtypes, parasympathetic overactivity contributes through inappropriate , promoting and that exacerbate orthostatic stress, as seen in neurally mediated syncope. Neurotransmitter imbalances further delineate autonomic involvement, with low plasma norepinephrine levels in reflecting sympathetic underactivity, while hyperadrenergic forms of () show excessive upright norepinephrine exceeding 600 pg/mL, indicating overactive sympathetic drive. These imbalances can arise from central or peripheral origins: central issues, such as dysregulation in , disrupt higher-level autonomic control, whereas peripheral denervation, common in , affects postganglionic sympathetic fibers. Recent research highlights small fiber neuropathy in approximately 50% of chronic orthostatic intolerance cases, contributing to peripheral autonomic deficits through damage to unmyelinated nerve fibers that regulate and functions. Post-COVID-19 autonomic persistence represents an emerging aspect, with 2024 studies demonstrating prolonged sympathetic hyperactivity in patients with orthostatic intolerance, often linked to persistent affecting autonomic pathways and leading to sustained adrenergic surges. This dysfunction underscores the vulnerability of the autonomic system to viral triggers, amplifying orthostatic challenges in affected individuals.

Causes and Risk Factors

Primary Causes

Primary causes of orthostatic intolerance encompass idiopathic and genetic origins where no external triggers, such as medications or infections, are identifiable. Idiopathic forms, where no external triggers are identifiable, are common and often involve progressive autonomic neurodegeneration, as seen in (PAF), a rare disorder characterized by selective degeneration of peripheral postganglionic sympathetic neurons leading to without involvement. In PAF, symptoms typically emerge in , with orthostatic intolerance resulting from impaired norepinephrine release and failure, distinguishing it from other synucleinopathies like . Genetic factors play a significant role in primary orthostatic intolerance, particularly through mutations in the gene (SLC6A2), which encodes the NET protein responsible for norepinephrine . These mutations, such as the A457P variant, reduce NET function, leading to elevated synaptic norepinephrine levels and hyperadrenergic orthostatic intolerance, often presenting with and upon standing. Familial clustering occurs in (POTS) cases, a common subtype of orthostatic intolerance, with associations to (HLA) alleles like DQB1*06:09, which may confer immunogenetic susceptibility. Developmental origins are prominent in adolescent-onset primary orthostatic intolerance, where rapid physiological changes during disrupt autonomic regulation. Growth spurts and hormonal shifts, particularly fluctuations in females, can impair sensitivity and vascular compliance, exacerbating orthostatic symptoms without underlying pathology. These presentations often emerge post- in otherwise healthy individuals, underscoring the role of maturational autonomic immaturity in idiopathic cases. Autonomic dysfunction remains a shared feature across these primary etiologies, manifesting as inadequate and compensation during upright posture.

Secondary Causes

Secondary causes of orthostatic intolerance encompass a range of identifiable medical conditions, medications, and external factors that impair autonomic regulation or hemodynamic responses upon postural change. These differ from primary forms by being potentially treatable or reversible through addressing the underlying trigger, such as discontinuing an offending agent or managing the precipitating illness. Among medical conditions, diabetic autonomic neuropathy is a prominent contributor, where cardiovascular autonomic dysfunction leads to impaired sensitivity and in patients with long-standing . In , orthostatic intolerance arises from central and peripheral autonomic degeneration, with a pooled prevalence of estimated at 30.1% across studies, often worsening with disease progression. Systemic , particularly light-chain (AL) type, infiltrates autonomic nerves and cardiac tissue, resulting in neurogenic as a common early manifestation, sometimes severe enough to cause syncope. Post-viral syndromes also play a role; for instance, orthostatic intolerance affects a substantial proportion (up to 30%) of individuals with , linked to persistent autonomic dysregulation following infection, while similar patterns occur after Epstein-Barr virus (EBV) in post-infectious fatigue syndromes. Connective tissue disorders, such as (EDS), are associated with due to vascular and autonomic abnormalities. Medications frequently induce orthostatic intolerance by altering vascular tone, , or . Antihypertensives, such as beta-blockers, are associated with a 6- to 7-fold increased odds of compared to , contributing to symptoms in up to 10% of users due to blunted responses. Diuretics promote through renal sodium and water loss, exacerbating postural drops in , while antidepressants impair norepinephrine in autonomic nerves, leading to orthostatic intolerance in susceptible individuals. Other triggers include acute or chronic states of volume depletion and physiological stressors. from gastrointestinal losses, such as or , reduces effective circulating volume and precipitates orthostatic symptoms, as does hypovolemia in endocrine disorders like , where causes sodium wasting and . Prolonged bedrest, common after or illness, induces deconditioning of mechanisms, increasing orthostatic intolerance risk within days. contributes via reduced oxygen-carrying capacity and compensatory , while often peaks in the second trimester due to venous pooling from uterine compression of the . Reports of orthostatic intolerance following , including vaccines, remain rare, with prevalence under 1% based on 2023 surveillance data, typically resolving without long-term sequelae. Many secondary causes are reversible; for example, medication-induced orthostatic intolerance frequently resolves upon discontinuation of the agent, and volume depletion responds to rehydration, highlighting the importance of identifying and mitigating these factors to alleviate symptoms.

Diagnosis

Clinical Evaluation

The clinical evaluation of orthostatic intolerance begins with a comprehensive to characterize the patient's symptoms, their onset, duration, and precipitating factors. Clinicians inquire about the timing of symptoms relative to postural changes, particularly or occurring within 10 minutes of standing, as well as exacerbating influences such as prolonged upright , heat exposure, or postprandial states. Family of similar complaints or autonomic disorders is elicited, alongside comorbidities like autoimmune conditions, diabetes, or chronic fatigue syndrome that may contribute to or mimic the presentation. Validated tools, such as the Orthostatic Grading Scale (OGS), a five-item self-report questionnaire assessing the frequency, severity, and functional impact of orthostatic symptoms on a 1-4 scale per item, aid in quantifying symptom burden and standardizing assessment. Physical examination focuses on orthostatic vital signs to identify hemodynamic instability. and are measured after 5-10 minutes , followed by immediate and 3-10 minute standing measurements; a systolic drop of ≥20 mmHg or diastolic drop of ≥10 mmHg within 3 minutes indicates , while a increase of ≥30 bpm (≥40 bpm in adolescents) without hypotension suggests (). Additional findings of autonomic dysfunction, such as dry skin, anhidrosis, sluggish , or abnormal sweating patterns, are sought to support the diagnosis. Red flags in the history or exam necessitate urgent evaluation to exclude life-threatening mimics. A history of unexplained syncope, frequent falls, or associated neurological deficits such as focal weakness, sensory loss, or ataxia prompts neuroimaging with MRI or CT to rule out central nervous system pathology like stroke or multiple system atrophy. Cardiac arrhythmias or structural heart disease should be considered in patients with exertional symptoms or abnormal cardiac exam, warranting electrocardiography. Initial laboratory investigations target reversible secondary causes. A (CBC) screens for , electrolytes and renal function assess for imbalances or , and fasting glucose or hemoglobin A1c evaluates for ; additional tests like function or levels may be indicated based on . These align with standardized protocols from the 2020 Canadian consensus on diagnosis, emphasizing exclusion of underlying etiologies before confirming primary orthostatic intolerance. During the consultation, basic is provided to empower self-management, explaining how gravitational shifts upon standing impair cerebral and the rationale for gradual postural transitions to mitigate symptoms.

Specialized Testing

Specialized testing for involves objective assessments to confirm the presence of hemodynamic abnormalities and reproduce symptoms under controlled conditions, distinguishing it from subjective clinical evaluation. Diagnostic criteria, established by a 2011 international consensus and refined in subsequent guidelines including a 2022 review, require chronic symptoms of lasting at least three to six months, accompanied by an abnormal orthostatic hemodynamic response such as a sustained heart rate increase of ≥30 beats per minute (or ≥40 bpm in adolescents) without for (POTS), or a drop in ≥20 mmHg or diastolic ≥10 mmHg within three minutes of standing for (OH). These criteria emphasize the integration of reproducible physiological changes with clinical symptoms to subtype the condition accurately. The active stand test serves as an accessible, non-invasive initial objective measure, performed by recording and after five minutes , followed by measurements at three and ten minutes of unsupported standing. Abnormalities are indicated by a increment exceeding 30 bpm (or 40 bpm in adolescents) from baseline without significant for , or a decline of >20 mmHg systolic or >10 mmHg diastolic for , with testing ideally using beat-to-beat monitoring for precision. This procedure, recommended in international guidelines, helps identify orthostatic intolerance in outpatient settings with high feasibility. Tilt-table testing provides a more standardized provocation of orthostatic , involving securing the patient on a table tilted to 60-80 degrees for 10-45 minutes while monitoring continuous , , and symptoms. It reproduces orthostatic intolerance symptoms in a majority of cases, with studies reporting diagnostic yields up to 80% sensitivity for confirming vasovagal syncope or when combined with hemodynamic recordings, surpassing the active stand test in controlled environments. An isoproterenol infusion challenge, administered at low doses (1-4 mcg/min) during tilting, enhances provocation of syncope or presyncope in non-responders, increasing test utility for neurally mediated subtypes without compromising safety. Advanced autonomic function tests target specific pathophysiological mechanisms. The quantitative sudomotor axon reflex test (QSART) evaluates postganglionic function by applying of to the skin and measuring sweat output via electrodermal response, revealing small fiber neuropathy in subsets of orthostatic intolerance patients, particularly those with or OH associated with autonomic impairment. Plasma , measured via blood draw, screen for hyperadrenergic states by detecting elevated catecholamine metabolites, guiding differentiation from conditions like in patients with exaggerated orthostatic or . Additionally, 24-hour Holter monitoring captures ambulatory electrocardiograms to identify arrhythmias, with studies showing detection rates of approximately 15% in orthostatic intolerance cohorts, including premature beats or supraventricular tachycardias that may exacerbate symptoms. Subtype-specific evaluations include to assess cardiac volume status and function, such as left ventricular or collapsibility, which can indicate contributing to orthostatic intolerance and inform fluid management decisions. Recent 2024 advancements incorporate wearable monitors for home-based testing, offering accuracy exceeding 90% for detection at rest compared to , enabling remote monitoring of orthostatic responses with devices like smartwatches to bridge gaps in clinical access while validating against criteria.

Management

Non-Pharmacological Approaches

Non-pharmacological approaches form the cornerstone of managing orthostatic intolerance (OI), focusing on lifestyle modifications to mitigate symptoms such as , , and upon postural changes. These strategies aim to address underlying factors like and venous pooling without relying on medications, often serving as first-line interventions particularly for conditions like (). Evidence supports their efficacy in improving orthostatic tolerance and , with individualized plans recommended based on symptoms and comorbidities. Increasing and intake is a primary recommendation to expand volume and counteract , a common contributor to OI. Patients are typically advised to consume 2-3 liters of fluids daily alongside 6-10 grams of , which can increase volume by 10-20% and thereby enhance orthostatic stability. garments, such as abdominal binders or thigh-high stockings providing 20-30 mmHg of , further reduce lower extremity blood pooling during upright posture, alleviating symptoms in many individuals. Physical countermeasures offer immediate relief during symptomatic episodes. Techniques such as leg crossing, , or tensing leg and abdominal muscles activate the pump to promote venous return and stabilize . Graduated exercise programs, starting with recumbent activities like biking for 10-20 minutes per session three to four times weekly, progressively build and reduce OI severity; recent protocols have shown symptom improvement in approximately 60-70% of patients after three to six months. Postural training strategies help prevent symptom exacerbation. Elevating the head of the bed by 4-6 inches (10-15 cm) overnight minimizes nocturnal and morning orthostatic stress, while avoiding triggers like hot showers or prolonged standing in warm environments reduces vasodilation-induced pooling. Pacing daily activities—such as breaking tasks into shorter intervals with rest periods—conserves energy and prevents . Behavioral interventions address the psychological overlap with OI, where anxiety can amplify symptoms. Cognitive behavioral therapy (CBT) assists patients in distinguishing physiological symptoms from anxiety, improving coping mechanisms and functional outcomes. School or work accommodations, such as 504 plans in the United States, provide flexibility like extended breaks, seating options, or reduced standing requirements to support daily participation. Regular home monitoring of and , using devices to log and standing values, enables patients to track symptom patterns and adjust interventions proactively. This self-management tool correlates with better adherence and earlier detection of triggers.

Pharmacological Interventions

Pharmacological interventions for orthostatic intolerance primarily target hemodynamic instability, autonomic dysfunction, and associated symptoms such as and , with treatments tailored to underlying subtypes like (POTS) or neurogenic orthostatic hypotension (nOH). Volume expanders are commonly used to increase plasma volume and mitigate orthostatic symptoms. , a , promotes sodium and water retention, typically administered at 0.1-0.2 mg daily to reduce orthostatic drops in patients with . Randomized studies indicate it improves standing compared to , though evidence quality is moderate due to small sample sizes. For acute flares, intravenous () saline infusions of 1-2 liters, administered intermittently (e.g., 3-7 times weekly), rapidly expand and alleviate symptoms in patients, with retrospective data showing significant symptom reduction in up to 79% of cases. Vasoconstrictors enhance peripheral to counteract . , an alpha-1 , is dosed at 5-10 mg three times daily (TID), taken while upright to avoid effects, and has demonstrated efficacy in improving standing systolic by 10-20 mmHg in clinical trials for . For nOH specifically, droxidopa, a norepinephrine precursor, at 100-600 mg TID increases upright and reduces , with pivotal trials showing symptom improvement in 50-60% of patients compared to . Beta-blockers address excessive tachycardia in POTS by modulating sympathetic outflow. Low-dose (10-40 mg daily, often 10-20 mg) blunts increases upon standing without excessively lowering , leading to symptom relief in randomized crossover studies where it reduced standing by 10-15 . , a selective of the funny current in the , offers a newer alternative at 5-7.5 mg twice daily (BID); in POTS and overlapping inappropriate sinus tachycardia has shown reduction without hemodynamic compromise in recent observational data, building on its FDA approval for chronic . Other agents target pathways or emerging neuroinflammatory aspects. , an , at 30-60 mg TID enhances ganglionic transmission to improve orthostatic tolerance, with open-label studies reporting symptom benefit in 43-51% of patients by increasing sensitivity without . Recent studies as of 2025, including clinical trials, have shown (1-4.5 mg daily) reduces pain and autonomic symptoms in and related via anti-inflammatory effects, with efficacy demonstrated in 50-60% of patients; ongoing research continues. Therapy initiation involves low starting doses with gradual (e.g., weekly increases based on response) to optimize while minimizing risks like supine hypertension, piloerection, or , common with vasoconstrictors. Monitoring includes serial orthostatic measurements, with response rates generally ranging from 50-70% across agents in clinical cohorts, though individual variability necessitates personalized adjustments.

Prognosis and Complications

Long-Term Outcomes

Orthostatic intolerance exhibits varied recovery patterns depending on age of onset and underlying . In adolescents, approximately 80% experience significant spontaneous improvement or full resolution over 5 years, often by early adulthood, with 19% achieving complete symptom resolution and 86% reporting resolved, improved, or intermittent symptoms at a mean follow-up of 5.4 years post-diagnosis. In chronic adult cases, outcomes are more persistent, with 99% reporting ongoing symptoms after a mean of 9.6 years; among these, 42% remain stable with little change, while 13% experience decline if untreated, though broader stability (including minor improvements) affects around 80% without progression to severe worsening. Prognostic factors significantly influence long-term trajectories. Early intervention, particularly with nonpharmacological strategies like increased fluid intake and graded exercise, enhances functional , with studies indicating up to 80% in symptoms with treatment, especially in adolescents. Primary forms of orthostatic intolerance, without associated systemic conditions, generally yield better outcomes than secondary forms linked to comorbidities like autoimmune disorders, where persistence is higher due to underlying disease progression. Adherence to management plays a key role in mitigating worsening. As of 2025, surveys indicate persistent symptoms in most adult cases, with only 26% able to work full-time. Quality-of-life metrics underscore persistent impairment in orthostatic intolerance. Longitudinal studies using the survey reveal physical domain scores below 50% of normal (e.g., mean 36.6 for physical composite), reflecting ongoing limitations in daily functioning and levels, with /fatigue subscales as low as 30. A 2023 follow-up indicated approximately 30% remission in select cohorts, though overall remission remains low at 19-31%. In post-COVID cases, approximately 72% exhibit moderate to severe autonomic dysfunction at a follow-up of 3 years. Annual reassessment is recommended to monitor progression and adjust strategies.

Associated Risks

Orthostatic intolerance significantly elevates the risk of falls and injuries, particularly through episodes of syncope, with affected individuals facing a 20-30% increased likelihood of such events compared to the general population. Symptoms such as dizziness and lightheadedness upon standing can exacerbate this vulnerability, leading to recurrent accidents and potential long-term physical harm. There is notable overlap with (ME/CFS), with approximately 60% of ME/CFS patients exhibiting orthostatic intolerance and up to 64% of patients meeting ME/CFS criteria, reflecting shared pathophysiological features like and autonomic dysfunction. Common comorbidities include hypermobile Ehlers-Danlos syndrome (hEDS), with joint hypermobility present in 18-55% of cases among those with orthostatic intolerance, often complicating vascular stability and integrity. activation disorders frequently co-occur, contributing to exaggerated inflammatory responses that worsen orthostatic symptoms. Additionally, chronic cardiovascular strain from repeated hypotensive episodes promotes , characterized by reduced aerobic capacity observed in nearly all patients. Secondary issues encompass challenges, with high prevalence of anxiety and (up to 87% in some studies), likely stemming from the chronic nature of symptoms and their impact on daily functioning. Nutritional deficits are also prevalent, arising from avoidance of meals in upright positions to prevent symptom flares, which can lead to inadequate intake and related health declines. In rare severe cases, orthostatic cerebral hypoperfusion may precipitate cognitive decline, with studies linking it to a 15% heightened long-term risk of due to recurrent underperfusion. 2025 neuroimaging research has identified abnormal cerebral perfusion in 61% of cases with cognitive dysfunction. Early intervention through targeted strategies can mitigate these risks, underscoring the importance of prompt recognition to prevent progression to complications.

References

  1. [1]
    Common Syndromes of Orthostatic Intolerance - PMC
    OI. Orthostasis means standing up. OI can be defined by the inability to tolerate the upright posture because of signs and symptoms relieved by lying down.
  2. [2]
    Orthostatic intolerance without postural tachycardia - NIH
    Orthostatic intolerance was defined as the development of previously defined symptoms of cerebral hypoperfusion or sympathetic activation upon standing along ...Table 1 · Table 2 · Abbreviations
  3. [3]
    Update on the theory and management of orthostatic intolerance ...
    Orthostasis means standing upright. One speaks of orthostatic intolerance (OI) when signs, such as hypotension, and symptoms, such as lightheadedness, occur ...Orthostatic Hypotension · Postural Tachycardia... · Postural Syncope (vvs, Acute...
  4. [4]
    Orthostatic Hypotension: Mechanisms, Causes, Management - PMC
    Jul 1, 2015 · Orthostatic intolerance refers to the development of symptoms such as lightheadedness and blurred vision when a subject stands up that ...Background · Maintenance Of Postural... · Patient Education
  5. [5]
    Orthostatic Intolerance - PMC - PubMed Central
    It is characterized by an exaggerated increase in heart rate (of more than 30 beats/minute) on standing with only a small decrease of blood pressure. This ...
  6. [6]
    Postural Orthostatic Tachycardia Syndrome - StatPearls - NCBI - NIH
    Epidemiology. As one of the most common forms of orthostatic intolerance globally, postural orthostatic tachycardia syndrome is estimated to affect over ...
  7. [7]
    Autoimmunity and postural orthostatic tachycardia syndrome
    Jul 1, 2023 · Postural orthostatic tachycardia syndrome (POTS) is a common form of orthostatic intolerance, with a prevalence of 0.2% to 1% in developed ...
  8. [8]
    The prevalence and impact of orthostatic intolerance in young ...
    Feb 27, 2022 · Orthostatic intolerance (OI) is frequently reported in young women with generalized hypermobility spectrum disorder (G-HSD) and hypermobile EDS (hEDS).<|control11|><|separator|>
  9. [9]
    Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar
    Mar 11, 2019 · Postural orthostatic tachycardia syndrome (POTS) is the most common form of orthostatic intolerance in young people (predominantly premenopausal ...
  10. [10]
    The face of postural tachycardia syndrome – insights from a large ...
    Mar 12, 2019 · POTS predominantly affects white (93%) females (94%) of childbearing age, with approximately half developing symptoms in adolescence (mode 14 ...Abstract · Materials and methods · Results · Discussion<|control11|><|separator|>
  11. [11]
    Epidemiology of Postural Tachycardia Syndrome (S18.005)
    Apr 9, 2019 · The most recent (2016) incidence rate was 6/100,000 person-year for the entire population (10.5/100,000 for women). The incidence rate among the ...
  12. [12]
    Postural tachycardia syndrome and other forms of orthostatic ...
    Feb 28, 2018 · ... Ehlers-Danlos syndrome and orthostatic intolerance. Results. We ... The 80% prevalence of objective orthostatic intolerance is similar ...
  13. [13]
    Prevalence and Clinical Impact of Postural Orthostatic Tachycardia ...
    Sep 30, 2025 · The remaining 196 (42%) participants were not tested for POTS as they neither reported typical symptoms of orthostatic intolerance nor ...
  14. [14]
    Dominant Transmission Observed in Adolescents and Families with ...
    Sep 24, 2016 · Orthostatic intolerance has previously been attributed to a pooling of blood in dependent vessels during upright positioning, leading to reduced ...
  15. [15]
    Gastrointestinal manifestations seen in pediatric patients diagnosed ...
    Autonomic dysfunction, including orthostasis and temperature dysregulation ... Keywords: autonomic dysfunction; postural orthostatic tachycardia syndrome; small ...
  16. [16]
    Poor health-related quality of life in postural orthostatic tachycardia ...
    Jun 20, 2023 · Compared with the normative population, the POTS cohort demonstrated significantly higher burden of impairment across all EQ-5D-5L domains (all ...
  17. [17]
    Orthostatic Hypotension - Cardiovascular Disorders - Merck Manuals
    Paradoxically, hypertension may contribute to poor baroreceptor sensitivity, increasing vulnerability to orthostatic hypotension. Older adults also have ...General References · History · TestingMissing: first | Show results with:first
  18. [18]
    Evaluation and Management of Orthostatic Hypotension - AAFP
    Sep 1, 2011 · Orthostatic hypotension may be acute or chronic. Patients may present with light-headedness, blurred vision, dizziness, weakness, and fatigue, ...Abstract · Pathophysiology · Clinical Presentation and... · Treatment
  19. [19]
    Chronic Orthostatic Intolerance | Circulation
    Chronic orthostatic intolerance (COI) is a disabling syndrome, characterized by pronounced tachycardia and symptoms such as fatigue, lightheadedness, dizziness ...
  20. [20]
    POTS-associated Conditions and Management Strategies
    Sep 19, 2023 · ... orthostatic intolerance lasting at least 3–6 months. Clinically, this condition is defined as: orthostatic intolerance associated with an ...
  21. [21]
    Postural Orthostatic Tachycardia Syndrome
    The current diagnostic criteria for POTS is a heart rate increase of 30 beats per minute (bpm) or more, or over 120 bpm, within the first 10 minutes of standing ...<|separator|>
  22. [22]
    Postural Orthostatic Tachycardia Syndrome is Associated with ... - NIH
    A study of 94 POTS patients published in 2003 found that only 25% of the study population was unable to work because of POTS [13]. This underestimates the ...<|control11|><|separator|>
  23. [23]
    Effect of postural changes on cardiovascular parameters... - Lippincott
    After 1 minute of standing, gravity induces roughly 500 mL of blood to shift to the lower body. After 20 to 30 minutes there is substantial loss of plasma ...
  24. [24]
    Effects of Gravity on Venous Return - CV Physiology
    When the person suddenly stands upright, gravity acts on the vascular volume, causing blood to accumulate in the lower extremities.
  25. [25]
    Mechanisms of sympathetic regulation in orthostatic intolerance - PMC
    Indeed, patients with ineffective sympathetic adrenergic vasoconstriction rapidly develop orthostatic hypotension, prohibiting effective upright activities. One ...
  26. [26]
    Orthostatic Hypotension: A Practical Approach - AAFP
    Orthostatic hypotension occurs in only 5% of middle-aged adults but affects approximately 20% of those 60 years and older. Prevalence in nursing homes and ...
  27. [27]
    Limb venous compliance in patients with idiopathic orthostatic ...
    Patients with orthostatic intolerance have reduced venous compliance in the lower extremity. Reduced compliance may limit the dynamic response to orthostatic ...
  28. [28]
    Cerebral Blood Flow in Orthostatic Intolerance
    Feb 3, 2025 · Many forms of orthostatic intolerance (OI) involve impaired regulation of CBF in the upright posture, which results in disabling symptoms that decrease quality ...
  29. [29]
    Orthostatic Intolerance: Background, Pathophysiology, Etiology
    Sep 27, 2025 · Orthostatic intolerance (OI) describes symptoms that occur when a ... Immediate Orthostatic Hypotension (IOH) upon stand Immediate ...
  30. [30]
    Persistent splanchnic hyperemia during upright tilt in postural ...
    Postural tachycardia syndrome (POTS) is a common illness characterized by symptoms of orthostatic intolerance in association with excessive upright tachycardia.
  31. [31]
    Cerebral blood flow is reduced in ME/CFS during head-up tilt testing ...
    Feb 8, 2020 · The underlying hypothesis in orthostatic intolerance (OI) syndromes is that symptoms are associated with cerebral blood flow (CBF) reduction.
  32. [32]
    Neurogenic Orthostatic Hypotension | Circulation
    Jan 6, 2009 · PD+NOH seems to be associated with more severe peripheral noradrenergic deficiency, whereas MSA seems to be associated with more severe central ...
  33. [33]
    Management of Orthostatic Hypotension - PMC - PubMed Central
    Plasma norepinephrine levels, Usually low (<200 pg/mL), Usually normal or high (>200 pg/mL), Depends on the level of the lesion. Cardiac MIBG or fluorodopamine ...
  34. [34]
    Neurally Mediated Syncope - PMC - PubMed Central - NIH
    Neurally mediated syncope is a disorder of the autonomic regulation of postural tone, which results in hypotension, bradycardia, and loss of consciousness.
  35. [35]
    The Postural Tachycardia Syndrome (POTS): Pathophysiology ...
    The supine norepinephrine is often high normal in patients with POTS, while the upright norepinephrine is usually elevated (>600 pg/ml), a reflection of the ...
  36. [36]
    Small fiber neuropathy in children, adolescents, and young adults ...
    Our data suggest a link between OI and POTS and small fiber neuropathy. Small fiber neuropathy was found by skin biopsy in over half of the patients tested.
  37. [37]
    Cardiovascular autonomic dysfunction in post-COVID-19 syndrome
    Jan 2, 2024 · CVAD is an important component of post-COVID-19 syndrome, also termed long COVID, and might affect one-third of highly symptomatic patients with COVID-19.
  38. [38]
    Pure Autonomic Failure - PMC - PubMed Central - NIH
    Sep 9, 2019 · Pure autonomic failure (PAF) is a neurodegenerative disorder of the autonomic nervous system clinically characterized by orthostatic hypotension.Missing: intolerance | Show results with:intolerance
  39. [39]
    A Mutation in the Human Norepinephrine Transporter Gene ...
    Recently, our laboratory reported a polymorphism in the human NET (hNET) gene A457P in an individual with the autonomic disorder orthostatic intolerance (OI).
  40. [40]
    Human Leukocyte Antigen Associations in Postural Tachycardia ...
    Apr 4, 2019 · Associations between human leukocyte antigen (HLA) and postural orthostatic tachycardia syndrome (POTS) have not been investigated.Missing: prevalence | Show results with:prevalence
  41. [41]
    Pubertal Hormonal Changes and the Autonomic Nervous System
    Puberty Is Associated With Orthostatic Intolerance. Puberty is a period of adolescence in which a child undergoes rapid changes that affect physical and mental ...
  42. [42]
    Orthostatic hypotension (postural hypotension) - Symptoms & causes
    May 26, 2022 · The most common symptom of orthostatic hypotension is lightheadedness or dizziness when standing after sitting or lying down. Symptoms usually ...Overview · When to see a doctor · Causes
  43. [43]
    Diabetic Cardiovascular Autonomic Neuropathy | Circulation
    Jan 23, 2007 · CAN is associated with a poor prognosis and may result in severe orthostasis, postural hypotension, exercise intolerance, enhanced ...
  44. [44]
    Prevalence of orthostatic hypotension in Parkinson's disease
    Mar 9, 2025 · The prevalence rate across studies ranged from 9.6% to 64.9% with an estimated pooled prevalence of 30.1% (95% CI: 22.9%–38.4%). Fig. 2 shows ...
  45. [45]
    Amyloidosis and autonomic failure - Mayo Clinic
    Jan 1, 2022 · Autonomic failure is usually a common predominant feature with orthostatic hypotension being the most frequent autonomic symptom.Missing: intolerance | Show results with:intolerance
  46. [46]
    Postural orthostatic tachycardia syndrome in post-COVID-19 long ...
    As many as 80% of coronavirus disease 2019 (COVID-19) long-hauler patients meet the diagnostic criteria for POTS, highlighting awareness of this debilitating ...
  47. [47]
    Drug-induced orthostatic hypotension: A systematic review and meta ...
    Nov 9, 2021 · Orthostatic hypotension (OH) is a common side effect of drugs. · Over 250 medications are associated with OH. · However, there is conflicting ...
  48. [48]
    Medication Causes of Orthostatic Hypotension - FPnotebook
    Medication Causes of Orthostatic Hypotension ; Tricyclic Antidepressants (e.g. Amitriptyline, Doxepin, Trazodone) ; Parkinsonism agents (Levodopa-Carbidopa, ...<|control11|><|separator|>
  49. [49]
    Orthostatic Hypotension: Management of a Complex, But Common ...
    Feb 25, 2022 · The prevalence of OH in the general population is strongly correlated with age, ranging from <5% below age 50% to 20% above age 70.
  50. [50]
    Pooled rates and demographics of POTS following SARS-CoV-2 ...
    Our study showed that POTS occur more frequently following SARS-CoV-2 infection than COVID-19 vaccination. Abstract. Purpose. To address recent concerns of ...
  51. [51]
    The Orthostatic Grading Scale (OGS) and the Symptom Screen for ...
    Initial evidence suggests that the OGS and SSS have good psychometric properties for use in populations with suspected and confirmed POTS.
  52. [52]
    Diagnosis and management of postural orthostatic tachycardia ...
    Mar 14, 2022 · Some patients have symptoms of orthostatic intolerance in the absence of orthostatic tachycardia and hypotension, and a cause cannot be found.Table 1 · How Is Pots Treated? · Table 2
  53. [53]
    Orthostatic hypotension (postural hypotension) - Diagnosis & treatment
    May 26, 2022 · For mild orthostatic hypotension, one of the simplest treatments is to sit or lie back down immediately after feeling lightheaded upon standing.
  54. [54]
    Diagnosis and treatment of orthostatic hypotension - PMC
    We propose a stepwise diagnostic approach for patients with symptoms that could relate to orthostatic hypotension (ie, orthostatic intolerance, syncope, falls, ...Clinical Presentation And... · Diagnostic Investigations Of... · Active Bedside Standing Test
  55. [55]
    Orthostatic Intolerance Clinical Presentation - Medscape Reference
    Sep 27, 2025 · Orthostatic intolerance immediately upon standing is highly specific for initial orthostatic hypotension (IOH). Neurogenic OH is associated with ...
  56. [56]
    [PDF] International Guidelines for Active Standing Test Procedure
    Orthostatic Hypotension (OH)​​ This is a fall in SBPs of >20 mmHg and/or a fall in DBP of >10 mmHg. If available, it is strongly receommended to use beat-to-beat ...
  57. [57]
    Tilt table test today - state of the art - PMC - NIH
    A tilt table test (TTT) is an inexpensive, noninvasive tool for the differential diagnosis of syncope and orthostatic intolerance and has good diagnostic yield.
  58. [58]
    Provocation of Hypotension During Head-Up Tilt Testing in Subjects ...
    This study was designed to evaluate the specificity of head-up tilt testing using different tilt angles and isoproterenol infusion doses in normal volunteers
  59. [59]
    Quantitative sudomotor axon reflex test (QSART) - Cleveland Clinic
    A QSART (quantitative sudomotor axon reflex test) examines the nerves that control your sweating. It detects autonomic nervous system issues.
  60. [60]
    Cardiac arrhythmias in postural tachycardia syndrome and ...
    Mar 7, 2022 · Results: In postural tachycardia syndrome/orthostatic intolerance patients, arrhythmia was detected on 15% of 332 ambulatory rhythm monitors. In ...
  61. [61]
    Accuracy of Wearable Monitors for Assessment of Heart Rate During ...
    Mar 27, 2024 · Wearable monitors were reasonably accurate at measuring heart rate during rest in NSR but much less accurate in atrial fibrillation or exercise.Missing: home orthostatic intolerance
  62. [62]
    Nonpharmacological Treatment of Postural Orthostatic Tachycardia ...
    Postural orthostatic tachycardia syndrome (POTS) is a type of autonomic dysfunction characterized by orthostatic intolerance (i.e., symptomatic hypotension ...<|control11|><|separator|>
  63. [63]
    Compression Garment Reduces Orthostatic Tachycardia ... - JACC
    This study investigated the effectiveness of body compression to reduce orthostatic tachycardia and improve orthostatic symptoms in adults diagnosed with POTS.
  64. [64]
    Postural orthostatic tachycardia syndrome (POTS) - Cleveland Clinic
    POTS is a condition that causes a number of symptoms when you transition from lying down to standing up, such as a fast heart rate, dizziness and fatigue.Postural Orthostatic... · Tilt Table Test · Qsart · Pyridostigmine Tablets<|control11|><|separator|>
  65. [65]
    Leg crossing with muscle tensing, a physical counter-manoeuvre to ...
    A physical counter-manoeuvre to postpone or even prevent orthostatic intolerance in these patients is leg crossing combined with muscle tensing.
  66. [66]
    Exercise in the Postural Orthostatic Tachycardia Syndrome - PMC
    Short-term (ie, 3 months) exercise training increases cardiac size and mass, blood volume, and VO 2peak in POTS patients.
  67. [67]
    Postural Orthostatic Tachycardia Syndrome (POTS)
    POTS is diagnosed only when orthostatic hypotension is ruled out and when there is no acute dehydration or blood loss.
  68. [68]
    A Case Study of Behavioral Treatment for Postural Orthostatic ...
    The patient learned to discriminate her POTS symptoms from anxiety and displayed a significant decrease in POTS-related functional impairment.
  69. [69]
    Management of Psychiatric Conditions in Patients With Comorbid ...
    Jan 31, 2023 · Cognitive-behavioral therapy (CBT) is a mainstay of psychological intervention for POTS, centered on developing awareness of the interaction ...
  70. [70]
    Classroom Accommodations for Children with Dysautonomia
    Children with dysautonomia often meet the requirements for a 504 plan, which provides protection from discrimination based on their medical disability. 504 ...
  71. [71]
    Orthostatic Intolerance Treatment & Management
    Sep 27, 2025 · If non-pharmacologic measures are insufficient, two medications have been approved for neurogenic causes of orthostatic hypotension: midodrine ...
  72. [72]
    Oral medications for the treatment of postural orthostatic tachycardia ...
    Jan 14, 2025 · The objective of this review is to provide an update on the overall state of the evidence for pharmacological management of POTS, and to ...
  73. [73]
    Fludrocortisone for orthostatic hypotension - Veazie, S - 2021
    May 17, 2021 · The randomized studies found that fludrocortisone reduced blood pressure drop compared to placebo (an inactive medication) in people with severe ...
  74. [74]
    Effects of intermittent intravenous saline infusions in patients with ...
    Intermittent IV infusions of saline dramatically reduce symptoms and improve quality of life in patients suffering from POTS.
  75. [75]
    Oral and intravenous hydration in the treatment of orthostatic ...
    In a retrospective study of 39 patients that received IV saline infusions of 1–2 L/day administered 3–7 days/week for OI, 79% of the patients had significant ...
  76. [76]
    Midodrine for orthostatic hypotension - PMC - NIH
    Dec 17, 2020 · Patients should begin midodrine at a low dose. This can be increased weekly according to the response. To reduce the risk of supine hypertension ...
  77. [77]
    A double-blind, placebo-controlled study with midodrine
    We conclude that midodrine is an effective and well-tolerated treatment for moderate-to-severe orthostatic hypotension associated with autonomic failure.
  78. [78]
    Droxidopa for neurogenic orthostatic hypotension - PubMed Central
    Conclusions: In patients with symptomatic nOH, droxidopa improved symptoms and symptom impact on daily activities, with an associated increase in standing ...
  79. [79]
    Droxidopa in neurogenic orthostatic hypotension - PubMed - NIH
    This article summarizes the pharmacological properties of droxidopa, its mechanism of action, and the efficacy and safety results of clinical trials.
  80. [80]
    Propranolol Decreases Tachycardia and Improves Symptoms in the ...
    Aug 17, 2009 · Low-dose oral propranolol significantly attenuated tachycardia and improved symptoms in POTS. Higher-dose propranolol did not further improve, and may worsen, ...
  81. [81]
    Efficacy of Propranolol, Bisoprolol, and Pyridostigmine for Postural ...
    Low-dose propranolol (10–20 mg orally) was more beneficial than high-dose propranolol (80 mg) for lowering the standing HR and improving the symptoms in POTS ...
  82. [82]
    Heart failure drug ivabradine shows promise for treating POTS ...
    Aug 29, 2025 · The drug, ivabradine, is typically used to treat chronic heart failure by slowing the heart rate without impacting blood pressure. In an ...
  83. [83]
    Ivabradine - StatPearls - NCBI Bookshelf
    Ivabradine is FDA-approved in the United States for use in patients with symptoms due to stable heart failure and an ejection fraction of 35% or less.
  84. [84]
    Pyridostigmine in the treatment of postural orthostatic tachycardia
    Mar 16, 2011 · Pyridostigmine improved symptoms of orthostatic intolerance in 88 of 203 (43%) of total patients or 88 of 172 (51%) who were able to ...
  85. [85]
    Pyridostigmine in the treatment of orthostatic intolerance - PubMed
    Feb 6, 2007 · Pyridostigmine bromide has been associated with improved baroreceptor sensitivity and presents a novel approach to treatment of orthostatic intolerance.<|separator|>
  86. [86]
    Low Dose Naltrexone Use in Patients With POTS | ClinicalTrials.gov
    There have been no research studies testing LDN in POTS to date. We are planning to do a research study to test LDN as a treatment to see if it helps POTS ...
  87. [87]
    Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms ...
    Jun 22, 2025 · The most common reason for prescribing LDN to patients in this study was pain or fibromyalgia (61.11%), followed by orthostatic intolerance ( ...
  88. [88]
    [PDF] Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia ...
    A diagnosis of. POTS was defined by orthostatic intolerance with a postural tachycardic increase of at least 40 beats per minute on 10- minute 70-degree head-up ...
  89. [89]
    Long‐Term POTS Outcomes Survey: Diagnosis, Therapy, and ... - NIH
    Jul 3, 2024 · It is theorized that postural orthostatic tachycardia syndrome (POTS) was likely first described in the medical literature in 1871 by Da Costa.<|separator|>
  90. [90]
    Overview of Postural Orthostatic Tachycardia Syndrome (POTS) for ...
    Feb 17, 2024 · Early intervention and appropriate management can improve symptoms. ... Psychological support, such as cognitive-behavioral therapy or counseling, ...<|separator|>
  91. [91]
    Postural Orthostatic Tachycardia Syndrome and Orthostatic ... - JACC
    Jun 17, 2025 · By day 100, 14.3% had POTS and 5.7% had OH, with no new cases and symptom resolution in 40% of POTS and 66.7% of OH cases. Download figure ...<|separator|>
  92. [92]
    Evaluating Long-Term Autonomic Dysfunction and Functional ...
    Oct 16, 2024 · Evidence of persistent moderate to severe autonomic dysfunction was seen in 71.9% of Long COVID patients in our study, with a 36-month median symptom duration.Missing: recovery | Show results with:recovery<|separator|>
  93. [93]
    Pediatric Postural Orthostatic Tachycardia Syndrome: Where We ...
    Jun 24, 2022 · Diagnostic criteria for pediatric POTS include symptoms of chronic orthostatic intolerance for ≥3 months, persistent symptomatic increase in ...Missing: estrogen | Show results with:estrogen
  94. [94]
    Risk of incident fractures in individuals hospitalised due to ...
    Aug 27, 2021 · Individuals hospitalised due to unexplained syncope and orthostatic hypotension have an increased risk of subsequent fractures.
  95. [95]
    Applying systems thinking to unravel the mechanisms underlying ...
    Apr 28, 2023 · Orthostatic hypotension (OH) is an established and common cardiovascular risk factor for falls ... syncope and severe orthostatic intolerance ...<|separator|>
  96. [96]
    Physiological assessment of orthostatic intolerance in chronic ... - NIH
    Feb 16, 2022 · Orthostatic intolerance-OI is common in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-ME/CFS. We used a 10-min passive vertical lean test ...
  97. [97]
    Prevalence of Hypermobile Ehlers-Danlos Syndrome in Postural ...
    Jan 10, 2020 · Self-Reported Ehlers-Danlos Syndrome Prevalence ... Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos ...
  98. [98]
    Postural orthostatic tachycardia syndrome and the potential role of ...
    If mast cell dysfunction has a causative role in the pathophysiology of POTS it could be expected that mastocytosis would be strongly associated with POTS.
  99. [99]
    Deconditioning in patients with orthostatic intolerance - PubMed - NIH
    Oct 2, 2012 · Reduced VO(2max)% consistent with deconditioning is present in almost all patients with orthostatic intolerance and may play a central role ...
  100. [100]
    Cognitive function, health-related quality of life, and symptoms of ...
    Jun 24, 2014 · From results obtained, it was concluded that participants with POTS have an increased prevalence of depression and higher levels of anxiety.<|control11|><|separator|>
  101. [101]
    Nutritional Implications of Patients with Dysautonomia and ...
    Sep 12, 2021 · Individualized diet strategies and supplements can reduce the multiorgan system symptoms observed in dysautonomia and hypermobility syndrome.
  102. [102]
    Orthostatic Hypotension and the Long-Term Risk of Dementia - NIH
    Oct 11, 2016 · Cerebral hypoperfusion is widely implicated in cognitive impairment, but whether OH contributes to cognitive decline and dementia is uncertain.
  103. [103]
    Novel brain SPECT imaging unravels abnormal cerebral perfusion ...
    Jan 28, 2025 · Cerebral blood flow during HUTT in young patients with orthostatic intolerance. Clin. Auton. Res. 25, 277–284 (2015). Article PubMed Google ...